Pharmacy and Therapeutics Newsletter Sept 2016

September 22, 2016 issue
Volume 16, Number 5

Table of contents

Enoxaparin Injection Sites

As we know, administration of subcutaneous enoxaparin (LOVENOX) should be alternated between
the left and right anterolateral and left and right posterolateral abdominal wall. Pharmacy has
received requests for administration to be made in areas such as the thigh. Research into alternate
site administration is limited. Only one study was found which compared enoxaparin administration
into the thigh versus the standard injection site. This study was conducted in obese patients and found
that when enoxaparin was injected into the thigh, anti Xa levels were found to be significantly lower.
Based on this limited information and the inability to monitor in-house anti Xa levels at CHS,
administration at the sites outlined by the manufacturer should be followed.

Formulary Additions

Loxapine Inhalation (ADASUVE) Read more here … pt-newsletter-16-5-092216pt

Formulary Additions for Lurie Pediatric Patients

  1. Ampicillin sulbactam (UNASYN) 1.5 GM for injection – added with pediatric restriction
  2. Cefotaxime (CLAFORAN) 500 mg, 1 GM, 2 GM for injection – added with pediatric restriction
  3. Ibuprofen chewable tablet 50 mg and 100 mg – added for pediatrics
  4. Montelukast (SINGULAR) 5 mg tablet – added for pediatrics
  5. Ranitidine (ZANTAC) 15 mg/mL Syrup – added for pediatrics
  6. Sodium Chloride 3% Nebs – added for pediatrics
    1. Vitamin A & D Ointment – added for pediatrics
  7. Sacchromyces boulardi (FLORASTOR) 250 mg capsule and packet – add for pediatric and adult patients

Formulary Deletions

  1. Alvimopan (ENTEREG) – Pharmacy will maintain supply until current stock expires. If this product has little or no use, it will be removed from formulary.
  2. Lidocaine 5%/D7.5W (PF) 100 mg/2 mL injection
  3. Bupivacaine-dextrose-water (PF) 15 mg/2 mL injection
  4. Heparin 1000 units/mL 30 mL MDV
  5. Tromethamine 36 mg/mL 500 mL solution for injection (THAM) – off market
  6. Sodium polystyrene sulfonate powder 454 GM

Therapeutic Substitutions

Drug OrderedDispensed With
Acetaminophen IV(OFIRMEV) 650 mg for nonpediatric patientsAcetaminophen IV (OFIRMEV) 1000 mg
Zolpidem CR (AMBIEN CR) 12.5 mg or 6.25 mgZolpidem (AMBIEN) 5 mg
Brinzolamide (AZOPT) Ophthalmic Solution 1 drop tid affected eye(s).Dorzolamide (TRUSOPT) Ophthalmic Solution 1 drop tid affected eye(s).

Policy/Protocol Revision

7300–531PT Medication Order Duration Policy
This policy, which specifies medication order duration based on individual medication or medication class type, had previously been deleted. At the February, 2016 Pharmacy and Therapeutics Committee meeting, it was resurrected so that appropriate durations could be placed in Paragon.
The revision that was made at this time was reorganization to make incorporation into Paragon easier.

7300–621PT Argatroban Dosing and Monitoring per Pharmacy Protocol
This protocol has been used for many years without substantial change. It details Argatroban dosing and dose adjustment when the drug is used for heparin induced thrombocytopenia or heparin induced thrombocytopenia with thrombotic syndrome. The only change that was made at this time regards removal of wording for a paper order.

7300–690PT Pediatric Medication Preparation and Administration
This policy, recognizing that the pediatric population has significant specific needs, an interdisciplinary process is designed to ensure that pediatric medication therapy is prepared and dispensed in a safe, effective, and timely manner and that all medications administered to pediatric patients are given accurately, safely, and with proper technique for each method of administration. The change that was made to this policy was the removal of the 0.1 mL overfill on IM and subcutaneous medications drawn up by Pharmacy.